Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia

American Journal of Psychiatry

Volumn 167, Issue 4, 2010, Pages 444-450

  Kéri, Szabolcs ^a,b,c,d   Beniczky, Sándor ^a,b,c,d   Kelemen, Oguz ^a,b,c,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c DANISH EPILEPSY CENTRE   (Denmark)

^d BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; MOLECULAR MARKER; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P50;

ADULT; ARTICLE; B LYMPHOBLAST; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; MALE; NEUROPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADULT; COGNITION DISORDERS; EVOKED POTENTIALS, AUDITORY; FEMALE; HIPPOCAMPUS; HUMANS; MALE; NEUREGULIN-1; NUCLEUS ACCUMBENS; PHOSPHORYLATION; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS C-AKT; SCHIZOPHRENIA; SENSORY GATING; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; WECHSLER SCALES;

EID: 77950614376     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.09050723     Document Type: Article

References (41)

1. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant A D, Swerdlow NR : Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007;33:69-94
2. Freedman R, Adams CE, Adler LE, Bickford PC, Gault J, Harris JG, Nagamoto H T, Olincy A, Ross RG, Stevens KE, Waldo M, Leonard S : Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. Am J Med Genet 2000;97:58-64
3. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W : Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997;94:587-592
4. Light GA, Braff DL : Do self-reports of perceptual anomalies reflect gating deficits in schizophrenia patients? Biol Psychiatry 2000;47:463-467
5. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S : Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004;70:315-329
6. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH : A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res 2007;97:137-151
7. Patterson JV, Hetrick W P, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney WE Jr : P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008;158:226-247
8. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH : Failure to find P50 suppression deficits in young firstepisode patients with schizophrenia and clinically unaffected siblings. Schizophr Bull 2007;33:1319-1323
9. Olincy A, Martin L : Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. Am J Psychiatry 2005;162:43-49
10. Martin LF, Hall M-H, Ross RG, Zerbe G, Freedman R, Olincy A : Physiology of schizophrenia, bipolar disorder, and schizoaffective disorder. Am J Psychiatry 2007;164:1900-1906
11. Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, Ozaki N, Taguchi T, Tatsumi M, Kamijima K, Straub RE, Weinberger DR, Kunugi H, Hashimoto R : Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004;13:2699-2708
12. Koros E, Dorner-Ciossek C : The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect 2007;20:437-445
13. Sei Y, Ren-Patterson R, Li Z, Tunbridge EM, Egan MF, Kolachana BS, Weinberger DR : Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. Mol Psychiatry 2007;12:946-957
14. Kanakry CG, Li Z, Nakai Y, Sei Y, Weinberger DR : Neuregulin-1 regulates cell adhesion via an erbb2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. PLoS ONE 2007; 2: e1369
15. Beaulieu JM, Gainetdinov RR, Caron MG : Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009;49:327-347
16. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK, Biechele T, Petryshen TL, Moon R T, Haggarty SJ, Tsai LH : Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009;136:1017-1031
17. Harrison PJ, Law AJ : Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006;60:132-140
18. Mei L, Xiong WC : Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008;9:437-452
19. Liu Y, Ford B, Mann MA, Fischbach GD : Neuregulins increase alpha7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J Neurosci 2001;21:5660-5669
20. Zhong C, Du C, Hancock M, Mertz M, Talmage DA, Role LW : Presynaptic type III neuregulin 1 is required for sustained enhancement of hippocampal transmission by nicotine and for axonal targeting of alpha7 nicotinic acetylcholine receptors. J Neurosci 2008;28:9111-9116
21. Fisahn A, Neddens J, Yan L, Buonanno A : Neuregulin-1 modulates hippocampal gamma oscillations: implications for schizophrenia. Cereb Cortex 2009;19:612-618
22. Clementz BA, Blumenfeld LD, Cobb S : The gamma band response may account for poor P50 suppression in schizophrenia. Neuroreport 1997;8:3889-3893
23. Grunwald T, Boutros NN, Pezer N, von Oertzen J, Fernandez G, Schaller C, Elger CE : Neuronal substrates of sensory gating within the human brain. Biol Psychiatry 2003;53:511-519
24. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA : Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004;36:131-137
25. Lai WS, Xu B, Westphal KG, Paterlini M, Olivier B, Pavlidis P, Karayiorgou M, Gogos JA : Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 2006;103:16906-16911
26. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R, Kolachana BS, Straub RE, Meyer-Lindenberg A, Sei Y, Mattay VS, Callicott JH, Weinberger DR : Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008;118:2200-2208
27. First MB, Spitzer RL, Gibbon M, Williams JBW : Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC, American Psychiatric Publishing, Inc, 1996
28. Kay SR, Fiszbein A, Opler LA : The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
29. Adler LE, Hoffer LD, Wiser A, Freedman R : Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-1861 (Pubitemid 23356580)
30. Nagamoto H T, Adler LE, Waldo MC, Freedman R : Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry 1989;25:549-561
31. Arnfred SM : Exploration of auditory P50 gating in schizophrenia by way of difference waves. Behav Brain Funct 2006;2:6
32. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL : Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000;157:767-771
33. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, Tendolkar I, Bechdolf A, Pukrop R, Klosterkoetter J, Ruhrmann S : Sensory gating in schizophrenia: P50 and N100 gating in antipsychoticfree subjects at risk, first-episode, and chronic patients. Biol Psychiatry 2008;64:376-384
34. Devrim-Uçok M, Keskin-Ergen HY, Uçok A : P50 gating at acute and post-acute phases of first-episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1952-1956
35. Munafò MR, Thiselton DL, Clark TG, Flint J : Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 2006;11:539-546
36. Schmitt A, Parlapani E, Gruber O, Wobrock T, Falkai P : Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. Eur Arch Psychiatry Clin Neurosci 258 (suppl 5) : 35-39, 2008
37. Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL, Thomson PA, Porteous DJ, Cunningham-Owens DG, Johnstone EC, Lawrie SM : A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci 2006;9:1477-1478
38. Kéri S, Kiss I, Kelemen O : Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high-risk for psychosis. Mol Psychiatry 2009;14:118-119
39. Ide M, Ohnishi T, Murayama M, Matsumoto I, Yamada K, Iwayama Y, Dedova I, Toyota T, Asada T, Takashima A, Yoshikawa T : Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. J Neurochem 2006;99:277-287
40. Kéri S, Seres I, Kelemen O, Benedek G : Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. Neurochem Int 2009;55:606-609
41. Hong LE, Summerfelt A, Mitchell B D, McMahon R P, Wonodi I, Buchanan RW, Thaker GK : Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry 2008;65:1008-1016